LFCR (Lifecore Biomedical) Beta: 1.3790 (As of Jun. 29, 2026)


LFCR Lifecore Biomedical Inc LFCR
55 GF Score
Price $4.97
GF Value $6.52
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Lifecore Biomedical Beta?

Lifecore Biomedical LFCR -3.78% 55 Beta is 1.3790 as of Jun. 29, 2026. GuruFocus rates LFCR with a GF Score™ of 55/100 and a GF Value™ of $6.52 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-29), Lifecore Biomedical's Beta is 1.3790.


Lifecore Biomedical  (NAS:LFCR) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Lifecore Biomedical Beta Related Terms


Lifecore Biomedical Beta Historical Data

* Premium members only.

The historical data trend for Lifecore Biomedical's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical Beta Chart

Lifecore Biomedical Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.16 1.32 0.91 0.78 0.23

Lifecore Biomedical Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.23 0.10 -0.40 0.92

LFCR vs ANIK, DERM, ASRT: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Beta distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Beta falls into.


LFCR
55GF Score
Lifecore Biomedical Inc LFCR
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lifecore Biomedical Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.3790 mean?
Lifecore Biomedical (LFCR) has a Beta of 1.3790 as of Jun. 29, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Lifecore Biomedical and its competitors.
Is Lifecore Biomedical's Beta too high?
Lifecore Biomedical's current Beta is 1.3790. Overall, Lifecore Biomedical has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Beta compare to ANIK and DERM?
Lifecore Biomedical's Beta of 1.3790 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Lifecore Biomedical and its competitors. Lifecore Biomedical's current Beta is 1.3790. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.52, compared to a current price of $4.97 — trading 23.8% below its estimated fair value. The current Beta is 1.3790. Lifecore Biomedical's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current Beta is 1.3790 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lifecore Biomedical (LFCR) Overvalued in 2026?

Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued. The current stock price of $4.97 is trading 23.8% below its estimated GF Value™ of $6.52. GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.

Key valuation signals for LFCR:

  • Beta: 1.3790
  • GF Value™: $6.52 vs. price of $4.97 (23.8% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lifecore Biomedical Business Description

Other Exchanges LDE:Germany
Address 3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
55GF Score

Get the complete analysis for LFCR

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.97
Price
$6.52
GF Value